Table 7.
Demographic and clinicopathological characteristics of BrCa and control groups.
| Group | Total | Adjuvant | Metastatic | Neoadjuvant | Control |
|---|---|---|---|---|---|
| N | 132 | 52 | 19 | 15 | 46 |
| Age | |||||
| Mean (±SD) | 57.7 (±13.9) | 58.7 (±12.0) | 61.9 (±9.8) | 55.5 (±16.6) | 55.6 (±13.7) |
| Median (range) | 59.0 (0.0–83.0) | 60.5 (27.0–80.0) | 65.0 (44.0–75.0) | 51.0 (29.0–79.0) | 57.0 (26.0–83.0) |
| Grade | |||||
| 1 | 10 | 10 | - | - | |
| 2 | 25 | 19 | - | 6 | |
| 3 | 30 | 16 | 8 | 6 | |
| N/A | 21 | 7 | 11 | 3 | |
| Stage | |||||
| I | 15 | 15 | - | - | |
| II | 28 | 28 | - | - | |
| III | 9 | 9 | - | - | |
| IV | 19 | - | 19 | - | |
| N/A | 15 | - | - | 15 | |
| Lymphnode status | |||||
| Negative | 27 | 24 | - | 3 | |
| Positive | 33 | 26 | - | 7 | |
| N/A | 26 | 2 | 19 | 5 | |
| Tumor size (before surgery) | |||||
| ≤2 | 30 | 25 | - | 5 | |
| >2 and ≤6.5 | 33 | 26 | - | 7 | |
| N/A | 23 | 1 | 19 | 3 | |
| Metastatic sites | |||||
| Lung | 12 | - | 12 | - | |
| Skin | 1 | - | 1 | - | |
| Distantlymphnodes | 5 | - | 5 | - | |
| Pancreas | 1 | - | 1 | - | |
| Bone | 9 | - | 9 | - | |
| Liver | 4 | - | 4 | - | |
| Pleural | 1 | - | 1 | - | |
Abbreviations: BrCa = breast cancer, SD = standard deviation, N/A = Non-Available or Non-Applicable.